Skip to Content

Poliovirus Vaccine Live Oral (Systemic)

Primary: IM100

Commonly used brand name(s): Orimune.

Note: For a listing of dosage forms and brand names by country availability, see Dosage Forms section(s).


Immunizing agent (active)—


General considerations
Poliomyelitis, which occurs worldwide, is caused by poliovirus types 1, 2, and 3 {01} {02} {03}. In countries where poliovirus is still endemic, paralytic disease is most often caused by poliovirus type 1, less frequently by poliovirus type 3, and least frequently by poliovirus type 2 {01} {03}. The virus is transmitted from person to person primarily by direct fecal-oral contact; however, it also can be transmitted by indirect contact with infectious saliva or feces or by contaminated sewage or water {01} {03}.

Since the introduction of poliovirus vaccines, poliomyelitis control has been achieved in the Americas {01} {02} {04}. In the U.S., the last reported case of indigenously acquired poliomyelitis caused by poliovirus was in 1979 {02}. No cases have occurred in the Western Hemisphere since August 1991 {02}. These and other findings from national surveillance in countries of the Americas led to the 1994 certification by an international commission that the wild-type poliovirus transmission has been interrupted in the Americas, thus achieving a public health goal established by the Pan American Health Organization in 1985 {02} {05}.

However, these countries can remain free of poliomyelitis only by reducing or eliminating the risk of poliovirus importation {01} {04}. Imported wild-type polioviruses have been associated with outbreaks in Gambia, Oman, Malaysia, Namibia, the Netherlands, Jordan, and Taiwan {04} {06}. To prevent recurrent importation, the best long-term solution is to eradicate wild-type poliovirus reservoirs in polio-endemic countries that are major exporters of wild-type polioviruses {06}.

In 1988 the World Health Assembly, the governing body of the World Health Organization (WHO), adopted the goal of global poliomyelitis eradication by the year 2000 {01} {03} {07} {08} {09} {10}. The goal of poliovirus eradication initiative (PEI) is to eliminate the circulation of wild-type poliovirus {11}. PEI has reduced the number of reported poliomyelitis cases worldwide by more than 80%, and worldwide eradication of the disease by the year 2000 appears feasible {01} {02} {08} {11}.

To achieve the global eradication of poliomyelitis, the WHO has recommended the following four major strategies:    • High routine immunization coverage {09} {10} {12} {13} {14} {15}. Countries should aim to vaccinate at least 90% of infants against polio by 1 year of age through routine immunization services {09} {13}. Infants should receive poliovirus vaccine live oral (OPV) at birth and at 6, 10, and 14 weeks of age for a total of four doses {09} {10}. High levels of routine immunization coverage will reduce incidence of polio to low levels and set the stage for eradication {09}. Until global eradication is achieved, polio-free countries must maintain high levels of immunization coverage to protect themselves against importation of wild-type poliovirus {09}.
   • National immunization days (NIDs) {05} {09} {10} {12} {13} {14} {16} {17} {18}. Vaccination strategies for poliomyelitis control in regions other than the Americas have consisted primarily of routine immunization {17}. However, routine immunization alone is unlikely to be sufficient to interrupt wild-type poliovirus transmission in most tropical and subtropical regions {17}. Therefore, mass immunization campaigns called NIDs are necessary to stop wild-type poliovirus transmission in these regions {09} {17}. The WHO recommends that all children younger than 5 years of age be immunized, regardless of their prior immunization status {09} {13} {18}. Two rounds of immunization are conducted, usually 4 to 6 weeks apart {09} {18}. Each round should be conducted in a short period of time {09}. Some countries may be able to complete a round in 1 or 2 days, but in others a week may be required {09}. To decrease operational difficulties and produce the maximum effect from the dose administered, NIDs should be conducted during the cool, dry season {09}. Population immunity resulting from NIDs appears to be superior to that produced by routine immunization, probably because of passive spread of vaccine virus and seroconversion during the season for low levels of enterovirus transmission {09}. Interrupting transmission is easier when environmental factors inhibit spread of wild-type poliovirus and chains of transmission are few {09}.
   • Acute flaccid paralysis (AFP) surveillance {05} {09} {12} {13} {14} {19}. The purpose of AFP surveillance is to show convincingly that if there were any polio cases occurring, they would be detected {20}. Eradication of wild-type poliovirus requires that sensitive surveillance systems capable of identifying cases of polio be in place in every country {09}. Data from these surveillance systems also will be needed to certify eradication {09}. The asymmetric AFP of poliomyelitis typically caused by wild-type poliovirus can also be caused by enteroviruses other than poliovirus, notably enterovirus 71, as well as by the polio vaccine virus itself {09}. Experience also has shown that on occasion, atypical presentations of poliomyelitis may be mistaken clinically for Guillain-Barré syndrome (GBS), transverse myelitis, traumatic neuritis, or other paralytic conditions {09}. Since there are no absolute criteria that will permit polio to be identified on a clinical basis, the WHO recommends laboratory-based AFP surveillance for the purpose of polio eradication {09}. AFP surveillance requires immediate reporting of all cases of AFP in children younger than 15 years of age {09}. Cases are investigated rapidly; clinical and epidemiologic information and two stool samples are collected {09}. The stool samples must be transported under refrigeration to a certified laboratory that is part of the WHO global polio laboratory network {09} {19}. Each specimen is then tested using uniform techniques and standardized reagents {09}. Any poliovirus isolated must be characterized to determine whether it is a wild-type or of a vaccine strain {09}. In the advanced stages of eradication, stools from contacts of cases also may be tested {09}. Countries with adequate surveillance systems should find at least one case of AFP each year for every 100,000 children younger than 15 years of age {09}.
   • Mopping up {09} {12} {13} {14} {15}. Successful NIDs will reduce poliovirus transmission to a few final chains of transmission, typically persisting in densely populated areas where inadequate health services yield both low routine immunization coverage and poor performance during NIDs {09}. Surveillance data are used to identify these final reservoirs of wild-type poliovirus infection. Intensive localized immunization campaigns, referred to as “mopping up” campaigns, are conducted to interrupt these final chains {09}. Mopping up campaigns immunize all children younger than 5 years of age, regardless of prior immunization status, in the targeted district {09}. Two doses are delivered approximately 1 month apart {09}. To improve immunization coverage and ensure that the most difficult-to-reach children are immunized, OPV is taken from house to house {09}.

The key to poliovirus eradication and its certification is a global network of high-quality poliovirus laboratories capable of detecting wild-type virus at the time and place where it occurs {21}. A network of laboratories has been established by the WHO to conduct surveillance for wild-type poliovirus and to provide evidence for the certification of poliomyelitis eradication {21} {22}. These laboratories collaborate with national eradication programs in the detection, reporting, clinical investigation, and virologic testing of stool specimens obtained in connection with cases of AFP and, where indicated, from healthy children and the environment {21}. The disappearance of wild-type poliovirus is documented by determining whether isolates are wild-type or derived from a vaccine {21} {22}.

The strategies for eradication of poliomyelitis are based on immunization with OPV designed to interrupt transmission of the wild-type poliovirus and on surveillance for every possible case of poliomyelitis {15}. The successes achieved so far are attributable primarily to the widespread use of OPV, the vaccine recommended by the WHO {02} {09}. Continued progress in poliomyelitis elimination clearly necessitates the use of OPV in those countries in which wild-type poliovirus remains or recently has been endemic {02}. The Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) reaffirmed its support of the eradication program initiated by the WHO and the use of OPV for this purpose {01}.


Poliomyelitis (prophylaxis)—OPV is indicated for immunization of infants, children, adolescents up to 18 years of age, and adults at greater risk of exposure to poliovirus than the general population against poliomyelitis caused by poliovirus types 1, 2, and 3 {01} {02} {23} {24}. Unless otherwise contraindicated, all infants, all children, all adolescents up to 18 years of age, and adults at greater risk of exposure to poliovirus than the general population should be immunized against poliomyelitis {01} {02}.

Note: OPV is essential for polio eradication because of its superior ability to induce secretory immunity in the intestines, the primary site of poliovirus replication {09}. OPV is also preferred because it is administered orally, thus simplifying the logistics for and improving the safety of mass campaigns {09}. The low cost of OPV makes it readily available for use in both developing and industrialized countries {09}.
Both the ACIP of the CDC and the Committee on Infectious Diseases of the American Academy of Pediatrics (AAP) support the WHO's recommendations on the use of OPV in countries where the wild-type poliovirus has not been eradicated {01} {02}.


Physicochemical characteristics:
    Produced from a mixture of three types of attenuated polioviruses that have been grown on human diploid (MRC-5) cell cultures or that have been propagated in monkey kidney cell culture {01} {23} {24}. Poliovirus vaccine live oral (OPV) contains the live, attenuated polioviruses {01} {23} {24}.

Mechanism of action/Effect:

OPV induces intestinal immunity against poliovirus reinfection, which explains its effectiveness in controlling the wild-type poliovirus circulation {02}. In addition, OPV persists in the pharynx for 1 to 2 weeks and is excreted in the feces for several weeks or longer after administration {02}. Consequently, the vaccine virus can be transmitted to contacts, resulting in their immunization {02}. However, in rare cases vaccine-associated paralytic poliomyelitis (VAPP) can occur in these contacts as well as in those who are vaccinated {02}.

Protective effect

The effectiveness of OPV has been amply demonstrated by its success in the U.S. and in many other areas of the world in preventing poliomyelitis and in interrupting the circulation of wild-type polioviruses {25} {26}. OPV in a three-dose series results in sustained, probably lifelong, protection against paralytic disease caused by each of the three poliovirus serotypes in more than 95% of recipients {02} {25}.

Duration of protective effect

The limited data on antibody persistence suggest that immunity is prolonged and perhaps lifelong {02}.

Precautions to Consider


Adequate and well-controlled studies have not been done in humans {08}. Although no conclusive evidence documents the adverse effects of poliovirus vaccine live oral (OPV) in pregnant women and their developing fetuses, vaccination of pregnant women should be avoided {01} {26} {27}. However, OPV may be given to pregnant women who are at substantial risk of imminent exposure to poliovirus infection {26}.

Studies have not been done in animals {23}.

FDA Pregnancy Category C {23}.


Breast-feeding does not interfere with successful immunization against poliomyelitis with OPV {01}. Although high concentrations of antipoliovirus antibody in the breast milk of some mothers theoretically could interfere with the immunogenicity of OPV in breast-fed infants, no such association has been demonstrated {26}. Infants should be immunized according to the recommended schedule regardless of the infant's mode of feeding {26}.

Women who have not received the recommended immunizations before or during pregnancy may be immunized postpartum regardless of their breast-feeding status {26}.


Infants up to 6 weeks of age—Use is not recommended in the U.S. and Canada {23} {24}; however, the World Health Organization (WHO) recommends vaccination of infants at birth (see General considerations){09}{10} .

Infants and children 6 weeks of age and older—Pediatrics-specific problems that would limit the usefulness of this vaccine in children in this age group are not expected {23} {24}.


Appropriate studies on the relationship of age to the effects of poliovirus vaccine have not been performed in the geriatric population. However, geriatrics-specific problems that would limit the usefulness of this vaccine in the elderly are not expected.

Drug interactions and/or related problems
The following drug interactions and/or related problems have been selected on the basis of their potential clinical significance (possible mechanism in parentheses where appropriate)—not necessarily inclusive (» = major clinical significance):

Note: Combinations containing any of the following medications, depending on the amount present, may also interact with this medication.

» Immunosuppressants such as corticosteroids, alkylating agents, antimetabolites, or
» Radiation therapy    (because normal defense mechanisms are suppressed, the patient's antibody response to any of the poliovirus vaccines may be decreased; in addition, the use of a live virus vaccine, such as OPV, may potentiate the replication of the vaccine virus, possibly causing poliomyelitis infection secondary to the vaccine; therefore, OPV should not be administered to these patients {01}. The precaution does not apply to corticosteroids used as replacement therapy, for short-term [less than 2 weeks] systemic therapy or by other routes of administration that do not cause immunosuppression)

    (where there is a family history of congenital or hereditary immune deficiency conditions, the patient should not be vaccinated with OPV until his/her immune competence is demonstrated)

Live virus vaccines, other    (data are lacking on impairment of antibody responses to rubella, measles, mumps, or OPV when these vaccines are administered on different days within 1 month of each other; however, OPV and measles, mumps, and rubella virus vaccine live [or its individual component vaccines] can be administered at any time before, with, or after each other, if indicated)

Medical considerations/Contraindications
The medical considerations/contraindications included have been selected on the basis of their potential clinical significance (reasons given in parentheses where appropriate)— not necessarily inclusive (» = major clinical significance).

Note: There is no long-term carrier state of poliovirus in immunocompetent persons {03}. Once fecal virus excretion has ceased, the person is no longer a source of infection {03}. However, harboring of poliovirus may occur among immunocompromised persons {03}. Vaccine virus was recovered from the cerebrospinal fluid of a patient 1 year after poliovirus immunization and continually from the stools of two patients 17 and 25 months, respectively, after immunization {03}. In a patient with agammaglobulinemia, replication of vaccine virus persisted for at least 684 days {03}.
If OPV is inadvertently administered to a household contact of an immunodeficient patient, the patient and the recipient of OPV should avoid close contact for approximately 4 to 6 weeks after vaccination {01}. If this is not feasible, rigorous hygiene and hand washing after contact with feces (e.g., after diaper changing) and avoidance of contact with saliva (e.g., sharing food or utensils) may be an acceptable but a less effective alternative {01}. Maximum excretion of the vaccine virus occurs within 4 weeks after oral poliovirus vaccination {01}.

Except under special circumstances, this medication should not be used when the following medical problems exist:
» Debilitated condition, advanced or
» Illness, moderate or severe, with or without fever    (administration of OPV should be postponed or avoided; minor illnesses, such as mild upper respiratory infections, do not preclude administration of vaccine {24})

» Diarrhea, persistent or
» Viral infection or
» Vomiting, persistent    (the presence of other viruses, including poliovirus and other enteroviruses, in the intestinal tract may interfere with the replication of OPV and, therefore, with the final immunity)

» Immune deficiency conditions, congenital or hereditary, family history of or
» Immune deficiency conditions, primary or acquired    (OPV should not be administered to persons who have immunodeficiency disorders such as severe combined immunodeficiency syndrome, agammaglobulinemia, or hypoagammaglobulinemia, since these persons are at substantially increased risk for vaccine-associated paralytic poliomyelitis [VAPP] {01} {24})

    (OPV should not be administered to persons with altered immune states resulting from malignant diseases such as leukemia, lymphoma, or generalized malignancy {01} {24})

    (OPV should not be administered to persons whose immune systems have been compromised by therapy with corticosteroids, alkylating agents, antimetabolites, or radiation, or by human immunodeficiency virus [HIV] infection {01} {24})

    (OPV should not be used to vaccinate household contacts of immunodeficient patients {01} {24})

» Allergy to neomycin, polymyxin B, or streptomycin    (patients allergic to neomycin, polymyxin B, or streptomycin may be allergic to OPV because the vaccine contains trace amounts of neomycin, polymyxin B, and streptomycin, which are used in the production of the vaccine to prevent bacterial overgrowth in the viral culture; OPV is contraindicated in persons who previously have had an anaphylactic reaction to OPV or to these antibiotics {01})

Risk-benefit should be considered when the following medical problem exists
» Sensitivity to poliovirus vaccine

Side/Adverse Effects

Note: The available evidence indicates that administration of poliovirus vaccine live oral (OPV) does not measurably increase the risk for Guillain-Barré syndrome (GBS) {01} {27}. Preliminary findings from two studies in Finland led to a contrary conclusion in a review conducted by the Institute of Medicine (IOM) in 1993 {01} {27}. The investigators in Finland reported an apparent increase in the incidence of GBS that was temporally associated with a mass vaccination campaign during which OPV was administered to children and adults who had previously been vaccinated with poliovirus vaccine inactivated (IPV) {01}. However, after the IOM review was completed, these data were reanalyzed and an observational study was completed in the U.S. {01} {27} Neither the reanalysis nor the newly completed study provided evidence of a causal relationship between OPV administration and GBS {01} {02} {27}.
In rare instances, administration of OPV has been associated with vaccine-associated paralytic poliomyelitis (VAPP) in healthy recipients and their contacts {01}. No procedures are currently available for identifying persons, other than those with immunodeficiency, who are at risk for such adverse reactions {01}. Although this is a rare occurrence, vaccinees or their parents, and their close, personal contacts who are susceptible, should be informed of the risk {01}.
Between 1980 and 1994, a total of 125 cases of VAPP were reported in the U.S. {02} The incidence of VAPP after the first dose of OPV is approximately one case per 760,000 doses of OPV distributed, including recipient and contact cases {02}. The risk of a recipient case after the first dose of OPV is estimated to be one per 1.5 million doses; for a contact case resulting from exposure to a first-dose recipient it is one per 2.2 million doses {02}. For subsequent doses, the risk is substantially lower for both recipients and contacts {02}. The risk for VAPP in immunodeficient persons is 3200- to 6800-fold higher than that of immunologically healthy OPV recipients {02}.

The following side/adverse effects have been selected on the basis of their potential clinical significance (possible signs and symptoms in parentheses where appropriate)—not necessarily inclusive:

Those indicating need for medical attention
Incidence rare
Anaphylactic reaction {23}{24}(difficulty in breathing or swallowing; hives; itching, especially of soles or palms; reddening of skin, especially around ears; swelling of eyes, face, or inside of nose; unusual tiredness or weakness, sudden and severe)

Those indicating need for medical attention only if they continue or are bothersome
Incidence more frequent

Patient Consultation
As an aid to patient consultation, refer to Advice for the Patient, Poliovirus Vaccine Live Oral (Systemic) .

In providing consultation, consider emphasizing the following selected information (» = major clinical significance):

Before using this vaccine
»   Conditions affecting use, especially:
Sensitivity to poliovirus vaccine or allergy to neomycin, polymyxin B, or streptomycin

Use in children—Not recommended in infants up to 6 weeks of age in the U.S. and Canada; however, the World Health Organization (WHO) recommends vaccination of infants at birth (see General considerations )

Other medications, especially immunosuppressants or radiation therapy
Other medical problems, especially advanced debilitated condition; moderate or severe illness, with or without fever; persistent diarrhea or vomiting; viral infection; family history of congenital or hereditary immune deficiency conditions; or primary or acquired immune deficiency conditions

Patients on low-sugar diets should be cautioned that the oral solution form of poliovirus vaccine may be administered on a sugar cube

Proper use of this vaccine

» Proper dosing

Side/adverse effects
In rare instances (approximately one case in 760,000 doses of distributed vaccine), healthy persons who have taken the live oral polio vaccine (OPV) and healthy persons who are close contacts of adults or children who have taken OPV have been infected by the poliovirus and become paralyzed

Signs of potential side effects, especially anaphylactic reaction

General Dosing Information
Poliovirus vaccine live oral (OPV) is administered orally {23} {24}. The vaccine should not be administered parenterally {23} {24}.

In September 1994, an international commission announced that there had been no single case of wild-type virus poliomyelitis in the Americas for 3 years and, based on the evidence of the surveillance from every country in the Americas, the commission concluded that poliovirus transmission had been interrupted {20}. Despite the eradication of polio from the region, immunization activities must continue unabated until all countries worldwide have eliminated poliomyelitis {20}.

Poliovirus vaccine should be given at 2, 4, 12 to 18 months, and 4 to 6 years of age, for a total of four doses at or before school entry. For children who receive OPV only, the third dose may be given as early as 6 months of age {02}. An additional dose at school entry is not indicated for children who receive the third dose of the vaccine on or after their fourth birthdays {02}.

The considerations that support expanded use of poliovirus vaccine inactivated (IPV) or poliovirus vaccine inactivated enhanced-potency (eIPV) apply primarily to countries where wild-type poliovirus transmissions have been interrupted for several years {02}. OPV remains the vaccine of choice for global eradication in the following areas:    • Areas where wild-type poliovirus has recently been or is currently circulating {02}.
   • Most developing countries, where the higher cost of eIPV or IPV prohibits its use {02}.
   • Areas where inadequate sanitation necessitates an optimal mucosal barrier to wild-type virus circulation {02}.

In general, simultaneous administration of the most widely used live and inactivated vaccines does not impair antibody responses or increase rates of adverse effects. Vaccines recommended for administration at 12 to 15 months of age can be administered at either one or two visits. There are equivalent antibody responses and no clinically significant increases in the frequency of adverse events when diphtheria toxoid, tetanus toxoid, and pertussis vaccine (DTP); measles, mumps, rubella virus vaccine live; OPV; and Haemophilus influenzae type b conjugate vaccine (HbCV) are administered either simultaneously at different sites or at separate times. If a child might not be brought back for future vaccinations, all vaccines (including DTP [or DTaP]; measles, mumps, rubella virus vaccine live; OPV; varicella; HbCV; and hepatitis B vaccines) may be administered simultaneously, as appropriate to the child's age and previous vaccination status {01} {26}.

Antibody-containing blood products or immune globulin (IG) preparations do not appear to interfere with the immune response to OPV; OPV may be administered concurrently with immune globulins, if necessary.

To avoid hyperglycemia, OPV should not be administered on a sugar cube to a patient on a low-sugar diet.

For treatment of adverse effects
Recommended treatment includes:

   • For mild hypersensitivity reaction—Administering antihistamines and, if necessary, corticosteroids {28}. In mild anaphylaxis, antihistamines or subcutaneous epinephrine may be all that is necessary if the condition is progressing slowly and is not life-threatening, regardless of the organ or system affected {28}. Under these circumstances the risks associated with intravenous epinephrine administration outweigh the benefits {28}.
   • For severe hypersensitivity or anaphylactic reaction—Administering epinephrine. Antihistamines or corticosteroids also may be administered as required {28}. Epinephrine is the treatment of choice for severe hypersensitivity or anaphylactic reaction {28}. If the patient's condition is not stable, epinephrine should be infused. Norepinephrine may be preferred if there is no bronchospasm {28}. For bronchospasm, epinephrine should be given with corticosteroids {28}. Other bronchodilators, such as intravenous aminophylline or albuterol by nebulization, also should be considered {28}.

Oral Dosage Forms


Usual adult dose
Immunizing agent (active)
Oral, 0.5 mL {23} {24}.

Two doses administered not less than six and preferably eight weeks apart, with the third dose administered six to twelve months following the second dose {23}.

Two or three doses administered six to twelve weeks apart {24}.

Note: In the U.S. and Canada, OPV is not indicated for adults; eIPV is the poliovirus vaccine of choice in the U.S. and Canada when immunization is indicated for adults {01} {02} {23} {24}.

Usual pediatric dose
Immunizing agent (active)
Oral, 0.5 mL (U.S.) or 0.5 mL or 3 drops (Canada—specific dose depends on manufacturer) {23} {24}.


First dose—
U.S.: At 6 to 12 weeks of age, commonly with the first DTP inoculation at 2 months of age {23}.

Canada: Not earlier than 2 months of age {24}.

Second dose—
U.S.: Not less than six and preferably eight weeks after the first dose, commonly with the second DTP inoculation at 4 months of age {23}.

Canada: Six to twelve weeks after the first dose {24}.

Third dose—
U.S.: Eight to twelve months after the second dose, commonly with the measles, mumps, and rubella virus vaccine live and fourth DTP inoculations at 15 months of age, but may be administered at any time between 12 and 24 months of age {23}.

Canada: Six to twelve weeks after the second dose {24}.

Booster doses—
U.S.: Upon entering school, usually between 4 to 6 years of age {23}. However, this booster dose is not required in children who receive the third dose of the primary series on or after their fourth birthday {23}.

Canada: Eight to fifteen months after the third dose; during the first school year; and around 15 years of age {24}.

Note: U.S.—An optional additional dose may be administered at 6 months of age (along with the third DTP inoculation) in areas with a high risk of poliovirus exposure {23}.

Children up to 18 years of age who did not follow the above schedule:
U.S.—The first two doses should be administered not less than six weeks and preferably eight weeks apart, and the third dose should be administered six to twelve months following the second dose {23}.

Canada—Two doses six to twelve weeks apart, followed by the booster doses above {24}.

Note: When there are time constraints with regard to immunization, the vaccination schedule may be accelerated for infants and children up to 18 years of age so that the first dose may be given at or after 6 weeks of age, the second dose given 6 to 8 weeks later, and the third dose given 6 weeks to 12 months later. Moreover, the second and third doses may be given as close as 4 weeks apart if necessary {23} {24}.

Strength(s) usually available

The equivalent of 10 5.4 to 10 6.4 for Type 1, 10 4.5 to 10 5.5 for Type 2, and 10 5.2 to 10 6.2 for Type 3 of the median tissue culture infective dose [TCID 50] (quantity of virus estimated to infect 50% of inoculated cultures) of the U.S. Reference Poliovirus, Live, Attenuated, per 0.5 mL (Rx) [Orimune]{23}


Approximately 1,000,000 infectious particles of Type 1, approximately 100,000 infectious particles of Type 2, and approximately 300,000 infectious particles of Type 3, per 0.5 mL (Rx)[Generic] (I.A.F.)

Approximately 1,000,000 infectious particles of Type 1, approximately 100,000 infectious particles of Type 2, and approximately 300,000 infectious particles of Type 3, per 3-drop dose (Rx)[Generic] (Connaught)

Packaging and storage:
Preserve at a temperature that will maintain ice continuously in a solid state {23} {29}. Because of its sorbitol content, this vaccine may remain fluid at temperatures above -14 °C (+7 °F) {23}. If frozen, the vaccine must be completely thawed prior to use. Preserve thawed vaccine at a temperature between 2 and 8 °C (36 and 46 °F) {29}. Vaccine that has been thawed may be carried through a maximum of 10 freeze-thaw cycles, provided the temperature does not exceed 8 °C (46 °F) during the periods of thaw and provided the total cumulative duration of thaw does not exceed 24 hours {23} {29}. If the 24-hour period is exceeded, the vaccine must be used within 30 days, during which time it must be stored at a temperature between 2 and 8 °C (36 and 46 °F) {23}.

Note: Childhood vaccines that are currently included in the Expanded Programme on Immunization (EPI) of the World Health Organization (WHO) vary widely in terms of their thermostability {15}. The least stable is the trivalent OPV, composed of live, attenuated viruses that must retain infectivity in order to replicate within the vaccine recipient {15}.
In 1996, suppliers of OPV through the United Nations Children's Fund (UNICEF) introduced individual time and temperature vaccine vial monitors (VVMs) on each vial of OPV {15}. This technology also will be made available to other producers as soon as possible {15}. These VVMs, which can be tailored to the thermostability of the vaccine produced by each individual manufacturer, along with a relaxation in vaccine vial opening rules announced by EPI in 1995, will allow health centers to use a vial of OPV until it is empty, as long as it does not show signs of contamination by visual inspection and the VVM indicates that it has not been thermally inactivated {15}. Proper use of VVMs is expected to significantly reduce wastage of OPV {15}.

Preparation of dosage form:
The vaccine must be completely thawed prior to use {23} {29}.

The vaccine may be administered directly or mixed with distilled water, chlorine-free tap water, Syrup NF, or milk. Alternatively, it may be adsorbed on foods, such as bread, cake, or cube sugar.

The vaccine contains phenol red as a pH indicator {23}. The usual color of the vaccine is pink, although some containers of vaccine may exhibit a yellow coloration {23}. The color of the vaccine prior to use (red-pink-yellow) has no effect on the virus or efficacy of the vaccine {23}.

Auxiliary labeling:
   • For oral use only {23}.

Developed: 12/01/1998

  1. Centers for Disease Control and Prevention (CDC). Recommendations of the Advisory Committee on Immunization Practices: poliomyelitis prevention in the United States—introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. MMWR Morb Mortal Wkly Rep 1997; 46(RR-3): 1-25.
  1. The Committee on Infectious Diseases of the American Academy of Pediatrics (AAP). Poliomyelitis prevention: recommendations for use of inactivated poliovirus vaccine and live oral poliovirus vaccine. Pediatrics 1997; 99(2): 300-5.
  1. Dowdle WR, Birmingham ME. The biologic principles of poliovirus eradication. J Infect Dis 1997; 175 Suppl 1: S286-S292.
  1. Reichler MR, Kharabsheh S, Rhodes P, et al. Increased immunogenicity of oral poliovirus vaccine adminstered in mass vaccination campaigns compared with the routine vaccination program in Jordan. J Infect Dis 1997; 175 Suppl 1: S198-S204.
  1. de Quadros CA, Hersh BS, Olive JM, et al. Eradication of wild-type poliovirus from the Americas: acute flaccid paralysis surveillance, 1988-1995. J Infect Dis 1997; 175 Suppl 1: S37-S42.
  1. Reichler MR, Abbas A, Kharabsheh S, et al. Outbreak of paralytic poliomyelitis in highly immunized populations in Jordan. J Infect Dis 1997; 175 Suppl 1: S62-S70.
  1. Centers for Disease Control and Prevention (CDC). Update: mass vaccination with oral poliovirus vaccine—Asia and Europe, 1996. MMWR Morb Mortal Wkly Rep 1997; 45(42): 911-4.
  1. Cochi SL, Hull HF, Sutter RW, et al. Commentary: the unfolding story of global poliomyelitis eradication. J Infect Dis 1997; 175 Suppl 1: S1-S3.
  1. Hull HF, Birmingham ME, Melgaard B, et al. Progress toward global polio eradication. J Infect Dis 1997; 175 Suppl 1: S4-S9.
  1. WHO Collaborative Study Group on oral and inactivated polivirus vaccines. Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in the Gambia, Oman, Thailand. J Infect Dis 1997; 175 Suppl 1: S215-S227.
  1. Gary HE, Sanders R, Pallansch MA. A theoretical framework for evaluating the sensitivity of surveillance for detecting wild poliovirus: I. factors affecting detection sensitivity in a person with acute flaccid paralysis. J Infect Dis 1997; 175 Suppl 1: S135-S140.
  1. Okwo-Bele JM, Lobanov A, Biellik RJ, et al. Overview of poliomyelitis in the African region and current regional plan of action. J Infect Dis 1997; 175 Suppl 1: S10-S15.
  1. Centers for Disease Control and Prevention (CDC). Progress toward poliomyelitis eradication—Africa, 1996. MMWR Morb Mortal Wkly Rep 1997; 46(15): 321-5.
  1. Andrus JK, Banerjee K, Hull BP, et al. Polio eradication in the World Health Organization South-East Asia region by the year 2000: midway assessment of progress and future challenges. J Infect Dis 1997; 175 Suppl 1: S89-S96.
  1. Milstein JB, Lemon SM, Wright PF. Development of a more thermostable poliovirus vaccine. J Infect Dis 1997; 175 Suppl 1: S247-S253.
  1. Jian Z, Jing-jin Y, Linkins RW, et al. Effect of target age of supplemental immunization campaigns on polimyelitis occurrence in China. J Infect Dis 1997; 175 Suppl 1: S210-S214.
  1. Reichler MR, Aslanian R, Lodhi ZH, et al. Evaluation of oral poliovirus vaccine delivery during the 1994 national immunization days in Pakistan. J Infect Dis 1997; 175 Suppl 1: S205-S09.
  1. Birmingham ME, Aylward RB, Cochi SL, et al. National immunization days: state of the art. J Infect Dis 1997; 175 Suppl 1: S183-S188.
  1. Pinheiro FP, Kew OM, Hatch MH, et al. Eradication of wild poliovirus from the Americas: wild poliovirus surveillance-laboratory issues. J Infect Dis 1997; 175 Suppl 1: S43-S49.
  1. Salisbury DM, Ramsay ME, White JM, et al. Polio eradication: surveillance implications for the United Kingdom. J Infect Dis 1997; 175 Suppl 1: S156-S159.
  1. Hull BP, Dowdle WR. Poliovirus surveillance: building the global polio laboratory network. J Infect Dis 1997; 175 Suppl 1: S113-S116.
  1. Sanders R, Maher C, Aylward RB, et al. Development and coordination of the polio laboratory network in the western pacific region of the World Health Organization. J Infect Dis 1997; 175 Suppl 1: S117-S121.
  1. Orimune package insert (Lederle—US), Rev 5/93, Rec 8/97.
  1. Krogh CME, editor. CPS Compendium of pharmaceuticals and specialties. 33rd ed. Ottawa: Canadian Pharmacists Association; 1998. p. 1332.
  1. Murdin AD, Barreto L, Plotkin S. Inactivated poliovirus vaccine: past and present experience. Vaccine 1996; 14(8): 735-46.
  1. American Academy of Pediatrics. Poliovirus infections. In: Peter G, editor. 1997 Red book: report of the Committee on Infectious Diseases. 24th ed. Elk Grove Village, IL: American Academy of Pediatrics; 1997. p. 424-33.
  1. Centers for Disease Control and Prevention (CDC). Recommendations of the Advisory Committee on Immunization Practices: update—vaccine side effects, adverse reactions, contraindications, and precautions. MMWR Morb Mortal Wkly Rep 1996; 45(RR-12): 8-10.
  1. Fisher M. Treatment of acute anaphylaxis. BMJ 1995; 311: 731-3.
  1. The United States pharmacopeia. The national formulary. USP 23rd revision (January 1, 1995). NF 18th ed. (January 1, 1995). Rockville, MD: The United States Pharmacopeial Convention Inc; 1994. p. 1240.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.